Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2026)

Insight Molecular Diagnostics has disclosed Return on Sales across 7 years of filings, most recently posting 1.38% for Q1 2026.

• Return on Sales for Q1 2026 came in at 1.38%, down 135.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.04% (down 2.0% YoY), and the FY2025 annual result was 0.03%, up 4.0% from the prior year.
• Return on Sales came in at 1.38% for Q1 2026 at Insight Molecular Diagnostics, down from 0.15% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.15% in Q4 2025 to a low of 1.38% in Q1 2026.
• The 5-year median for Return on Sales is 0.29% (2022), against an average of 0.44%.
• Across the five-year window, Return on Sales soared 118 bps in 2023 and sank 135 bps in 2026, its largest moves.
• Insight Molecular Diagnostics' Return on Sales stood at 1.2% in 2022, then soared by 98 bps to 0.02% in 2023, then surged by 607 bps to 0.1% in 2024, then jumped by 52 bps to 0.15% in 2025, then tumbled by 1016 bps to 1.38% in 2026.
• The last three Return on Sales figures came in at 1.38% (Q1 2026), 0.15% (Q4 2025), and 0.42% (Q3 2025), per Business Quant data.